Join

Compare · CGIX vs LH

CGIX vs LH

Side-by-side comparison of Cancer Genetics, Inc. (CGIX) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CGIX and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
  • LH carries a market cap of $25.85B.
  • LH has hit the wire 7 times in the past 4 weeks while CGIX has been quiet.
  • LH has more recent analyst coverage (25 ratings vs 0 for CGIX).
MetricCGIXLH
Company
Cancer Genetics, Inc.
Labcorp Holdings Inc.
Price
-
$263.82-0.44%
Market cap
-
$25.85B
1M return
-
-
1Y return
-
-
Industry
Medical Specialities
Medical Specialities
Exchange
NASDAQ
NYSE
IPO
n/a
News (4w)
0
7
Recent ratings
0
25
LH

Labcorp Holdings Inc.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.